The Evolving Landscape of Nano-Emulsion Drug Systems in diabetes: Updated Review

Abstract

The use of Nano emulsion in augmenting dermal and
transdermal effectiveness of drugs has now well established.
The development of Nano emulsion based semisolid dosage
forms is an active area of present research. The thickening or
liquid-to-semisolid conversion of the nano-emulsions provides
opportunities to the formulation scientist to explore novel means
of solving instability issues during transformation. Conventional
dosage forms of the anti-diabetic drugs exhibit variable/less
bioavailability and short half-life, demanding frequent dosing
and causing increased side-effects resulting in ineffectiveness of
therapy and non-compliance with the patients. Considering the
chronic nature of diabetes, nanotechnology-based approaches
are more promising in terms of providing site-specific delivery
of drugs with higher bioavailability and reduced regimen. Many
studies have hinted at the possibility of administering peptide
drugs like glucagon like peptides orally by encapsulation into
nanoparticles. Nanoparticles also allow further modifications
including their encapsulation into micro-particles, polyethylene
glycol (PEG)-PEGylation- or functionalization with ligands for
active targeting.